Preventing MEK1 activation influences the responses of human osteosarcoma cells to bone morphogenetic proteins 2 and 9

Anti-Cancer Drugs

Volumn 24, Issue 3, 2013, Pages 278-290

  Park, Hyunjin ^a   Drevelle, Olivier ^a   Daviau, Alex ^a   Senta, Helena ^a,b   Bergeron, Eric ^a,c   Faucheux, Nathalie ^a,b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^c ÉCOLE POLYTECHNIQUE DE MONTRÉAL   (Canada)

Author keywords

extracellular signal regulated kinase 1 2; MG 63; osterix; p38; peptides derived from bone morphogenetic proteins; proliferation; SaOS 2; Smad

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 9; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR OSTERIX;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HOMEOBOX; HUMAN; HUMAN CELL; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; BONE MORPHOGENETIC PROTEIN 2; BONE NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH DIFFERENTIATION FACTOR 2; HOMEODOMAIN PROTEINS; HUMANS; MAP KINASE KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOLECULAR SEQUENCE DATA; OSTEOSARCOMA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; SMAD PROTEINS; TRANSCRIPTION FACTORS;

EID: 84873411450     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835cbde7     Document Type: Article

References (52)

1. Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2007; 2:6
2. Gorlick R, Khanna C. Osteosarcoma. J Bone Miner Res 2010; 25: 683-691
3. Luo X, Chen J, Song WX, Tang N, Luo J, Deng ZL, et al. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest 2008; 88:1264-1277
4. Wang L, Park P, Zhang H, La Marca F, Claeson A, Valdivia J, et al. BMP-2 inhibits the tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cell line. Cancer Biol Ther 2011; 11:457-463
5. Brown MA, Zhao Q, Baker KA, Naik C, Chen C, Pukac L, et al. Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem 2005; 280:25111-25118
6. Kirsch T, Nickel J, Sebald W. BMP-2 antagonists emerge from alterations in the low-Affinity binding epitope for receptor BMPRII. EMBO J 2000; 19:3314-3324
7. Sieber C, Kopf J, Hiepen C, Knaus P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev 2009; 20:343-355
8. Kugimiya F, Ohba S, Nakamura K, Kawaguchi H, Chung U. Physiological role of bone morphogenetic proteins in osteogenesis. J Bone Miner Metab 2006; 24:95-99
9. Franceschi RT, Ge CX, Xiao GZ, Roca H, Jiang D. Transcriptional regulation of osteoblasts. Ann NY Acad Sci 2007; 1116:196-207
10. Kuo PL, Hsu YL, Chang CH, Chang JK. Osthole-mediated cell differentiation through bone morphogenetic protein-2/p38 and extracellular signalregulated kinase 1/2 pathway in human osteoblast cells. J Pharmacol Exp Ther 2005; 314:1290-1299
11. Zhang Y, Dong C. Regulatory mechanisms of mitogen-Activated kinase signaling. Cell Mol Life Sci 2007; 64:2771-2789
12. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007; 26:3100-3112
13. Burkus JK, Heim SE, Gornet MF, Zdeblick TA. The effectiveness of rhBMP-2 in replacing autograft: An integrated analysis of three human spine studies. Orthopedics 2004; 27:723-728
14. McKay WF, Peckham SM, Badura J. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft). Int Orthop 2007; 31:729-734
15. Kang Q, Sun MH, Cheng H, Peng Y, Montag AG, Deyrup AT, et al. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 2004; 11:1312-1320
16. Jiang WG. BMP-9 and BMP-10 and their use in breast and prostate cancer therapies, patent WO/2008/015383; 2008
17. Ye L, Kynaston H, Jiang WG. Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol Cancer Res 2008; 6:1594-1606
18. Saito A, Suzuki Y, Ogata SI, Ohtsuki C, Tanihara M. Activation of osteoprogenitor cells by a novel synthetic peptide derived from the bone morphogenetic protein-2 knuckle epitope. Biochim Biophys Acta 2003; 1651:60-67
19. Bergeron E, Senta H, Mailloux A, Park H, Lord E, Faucheux N. Murine preosteoblast differentiation induced by a peptide derived from bone morphogenetic proteins-9. Tissue Eng Part A 2009; 15:3341-3349
20. Suzuki Y, Tanihara M, Suzuki K, Saitou A, Sufan W, Nishimura Y. Alginate hydrogel linked with synthetic oligopeptide derived from BMP-2 allows ectopic osteoinduction in vivo. J Biomed Mater Res 2000; 50:405-409
21. Bergeron E, Leblanc E, Drevelle O, Giguè re R, Beauvais S, Grenier G, et al. The evaluation of ectopic bone formation induced by delivery systems for bone morphogenetic protein-9 or its derived peptide. Tissue Eng Part A 2012; 18:342-352
22. Krattinger N, Applegate LA, Biver E, Pioletti DP, Caverzasio J. Regulation of proliferation and differentiation of human fetal bone cells. Eur Cell Mater 2011; 21:46-58
23. Buijs JT, van der Horst G, van den Hoogen C, Cheung H, de Rooij B, Kroon J, et al. The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation. Oncogene 2012; 31:2164-2174
24. Franceschi RT, James WM, Zerlauth G. 1a, 25-Dihydroxyvitamin D3 specific regulation of growth, morphology, and fibronectin in a human osteosarcoma cell line. J Cell Physiol 1985; 123:401-409
25. Rodan SB, Imai Y, Thiede MA, Wesolowski G, Thompson D, Bar-Shavit Z, et al. Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res 1987; 47:4961-4966
26. Pautke C, Schieker M, Tischer T, Kolk A, Neth P, Mutschler W, et al. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res 2004; 24:3743-3748
27. Shapira L, Halabi A. Behavior of two osteoblast-Like cell lines cultured on machined or rough titanium surfaces. Clin Oral Implants Res 2009; 20:50-55
28. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD98059 is a specific inhibitor of the activation of mitogen-Activated protein kinase in vitro and in vivo. J Biol Chem 1995; 270:27489-27494
29. Noh K, Kim KO, Patel NR, Staples JR, Minematsu H, Nair K, et al. Targeting inflammatory kinase as an adjuvant treatment for osteosarcomas. J Bone Joint Surg Am 2011; 93:723-732
30. de Laszloe SE, Viscob D, Agarwalb L, Change L, China J, Crofta G, et al. Pyrroles and other heterocycles as inhibitors of P38 kinase. Bioorg Med Chem Lett 1998; 8:2689-2694
31. Robitaille K, Daviau A, Lachance G, Couture JP, Blouin R. Calphostin C-induced apoptosis is mediated by a tissue transglutaminase-Dependent mechanism involving the DLK/JNK signaling pathway. Cell Death Differ 2008; 15:1522-1531
32. Karlen Y, McNair A, Perseguers S, Mazza C, Mermod N. Statistical significance of quantitative PCR. BMC Bioinformatics 2007; 8:131
33. Yuan JS, Reed A, Chen F, Stewart CN Jr. Statistical analysis of real-Time PCR data. BMC Bioinformatics 2006; 7:85
34. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2 DDCt method. Methods 2001; 25:402-408
35. Guicheux J, Lemonnier J, Ghayor C, Suzuki A, Palmer G, Caverzasio J. Activation of p38 mitogen-Activated protein kinase and c-Jun-NH2-Terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 2003; 18:2060-2068
36. Lee MH, Kim YJ, Kim HJ, Park HD, Kang AR, Kyung HM, et al. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-b1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 2003; 278:34387-34394
37. Lee MH, Kwon TG, Park HS,Wozney JM, Ryoo HM. BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2. Biochem Biophys Res Commun 2003; 309:689-694
38. Xiao ZS, Liu SG, Hinson TK, Quarles LD. Characterization of the upstream mouse Cbfa1/Runx2 promoter. J Cell Biochem 2001; 82:647-659
39. Nakashima K, Zhou X, Kunkel G, Zhang ZP, Deng JM, Behringer RR, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002; 108:17-29
40. Ulsamer A, Ortun?o MJ, Ruiz S, Susperregui AR, Osses N, Rosa JL, et al. BMP-2 induces Osterix expression through up-regulation of Dlx5 and its phosphorylation by p38. J Biol Chem 2008; 283:3816-3826
41. Park H, Bergeron E, Senta H, Guillemette K, Beauvais S, Blouin R, et al. Sanguinarine induces apoptosis of human osteosarcoma cells through the extrinsic and intrinsic pathways. Biochem Biophys Res Commun 2010; 399:446-451
42. Kawano M, Ariyoshi W, Iwanaga K, Okinaga T, Habu M, Yoshioka I, et al. Mechanism involved in enhancement of osteoblast differentiation by hyaluronic acid. Biochem Biophys Res Commun 2011; 405:575-580
43. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-Like kinase 1 (ALK1) in endothelial cells. Blood 2007; 109:1953-1961
44. Luo J, Tang M, Huang J, He BC, Gao JL, Chen L, et al. TGF b/BMP type I receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in mesenchymal stem cells. J Biol Chem 2010; 285: 29588-29598
45. Gobbi G, Sangiorgi L, Lenzi L, Casadei R, Canaider S, Strippoli P, et al. Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. Int J Oncology 2002; 20:143-147
46. Lord E, Bergeron E, Senta H, Park H, Faucheux N. Effect of BMP-9 and its derived peptide on the differentiation of human white preadipocytes. Growth Factors 2010; 28:149-156
47. Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T, et al. Runx2 is a common target of transforming growth factor b1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000; 20:8783-8792
48. Cao Y, Zhou Z, de Crombrugghe B, Nakashima K, Guan H, Duan X, et al. Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma. Cancer Res 2005; 65: 1124-1128
49. Shimo T, Matsumura S, Ibaragi S, Isowa S, Kishimoto K, Mese H, et al. Specific inhibitor of MEK-mediated cross-Talk between ERK and p38 MAPK during differentiation of human osteosarcoma cells. J Cell Commun Signal 2007; 1:103-111
50. Kloesch B, Hoering B, Dopler D, Banerjee A, van Griensven M, Redl H. Synthetic peptides derived from the knuckle epitope of hBMP-2 were evaluated for inducing osteogenic differentiation in vitro and in vivo. Eur Cell Mater 2007; 14:70
51. Huang W, Rudkin GH, Carlsen B, Ishida K, Ghasri P, Anvar B, et al. Overexpression of BMP-2 modulates morphology, growth, and gene expression in osteoblastic cells. Exp Cell Res 2002; 274:226-234
52. Liu L, Zhu Y, Xu Y, Reiter RJ. Prevention of ERK activation involves melatonin-induced G(1) and G(2) /M phase arrest in the human osteoblastic cell line hFOB 1.19. J Pineal Res 2012; 53:60-66